Remitting Seronegative Symmetrical Synovitis with Pitting Oedema

Remitting Seronegative Symmetrical Synovitis with Pitting Oedema: A Comprehensive Overview

Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) is an uncommon rheumatic disease that presents with distinctive clinical features affecting the peripheral joints and soft tissues. Also referred to as puffy oedematous hand syndrome and distal extremity swelling with pitting oedema, this condition is characterized by a benign course in most cases, though it may occasionally be associated with underlying malignancy. Understanding RS3PE is essential for healthcare providers to ensure prompt diagnosis and appropriate management, particularly given its excellent response to treatment and the need to screen for potential paraneoplastic associations.

Introduction and Definition

RS3PE syndrome represents a distinct subset of seronegative symmetrical polyarthritis with specific diagnostic criteria. The condition is characterized by symmetrical distal synovitis, tenosynovitis of the mucous sheaths of the flexor and extensor tendons of the hands, and pitting edema of the hands and/or feet. A defining feature of RS3PE is seronegativity for the Rheumatoid Factor (RF) and the absence of joint erosion, distinguishing it from other rheumatologic conditions. The syndrome is known for its exquisite response to corticosteroids and the potential for long-term remission after withdrawal of treatment, making it one of the more favorable rheumatologic diagnoses when identified correctly.

Demographics and Epidemiology

RS3PE predominantly affects elderly individuals, with the majority of cases occurring in patients over 60 years of age. The condition shows a marked male predominance, affecting males more frequently than females. However, case reports have documented presentations in younger individuals, including women under 50 years of age, suggesting that while uncommon in younger populations, RS3PE should not be entirely excluded based on age alone. The rarity of the condition means that many physicians may have limited experience with its diagnosis, leading to delays in recognition and treatment.

Clinical Features and Presentation

The clinical presentation of RS3PE is relatively distinctive and typically begins with acute onset symptoms. Patients typically present with:

• Acute-onset polyarthritis affecting the peripheral joints bilaterally and symmetrically
• Prominent pitting edema on the dorsum of the hands and feet
• Painful swelling in both hands and feet, often of sudden onset
• Active synovitis in the wrists, metacarpophalangeal joints, proximal interphalangeal joints, metatarsophalangeal joints, and ankles
• Limitation of grip strength and functional impairment in manual activities
• Tenosynovitis affecting the flexor and extensor tendons of the hands

The pitting edema is a hallmark feature, distinguishing RS3PE from other conditions. This edema is particularly notable on the dorsum of the hands, and when pressure is applied, an indentation remains temporarily. Patients frequently report significant functional impairment, with some unable to perform basic activities of daily living. The onset is typically rapid, with symptoms developing over days to weeks rather than following an insidious course.

Associated Features and Systemic Manifestations

While RS3PE is primarily a disorder affecting the peripheral joints and soft tissues, certain systemic features may accompany the presentation, particularly when an underlying malignancy is present. Patients may experience general malaise, fatigue, and functional decline. Laboratory investigations often reveal:

• Elevated inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein
• Normocytic, normochromic anemia in some cases
• Normal renal and hepatic function tests
• Negative serological tests for rheumatoid factor and antinuclear antibodies
• Negative tests for anti-cyclic citrullinated peptide antibodies
• Negative antineutrophil cytoplasmic antibodies and extractable nuclear antigen panels

Imaging studies, including hand X-rays, typically show only an increase in soft tissue density without evidence of joint erosion or bony destruction. This absence of erosive changes is a key distinguishing feature from rheumatoid arthritis.

Causes and Associations

The etiology of RS3PE remains incompletely understood, with the condition being classified as either idiopathic or paraneoplastic. A significant association between RS3PE and underlying malignancy has been documented in the medical literature. Various malignancies have been reported in association with RS3PE, including:

• Papillary thyroid carcinoma
• Non-Hodgkin’s lymphoma
• Adenocarcinomas of unknown primary origin
• Other hematologic and solid malignancies

When malignancy is present, RS3PE functions as a paraneoplastic syndrome. The temporal relationship between the development of RS3PE symptoms and the diagnosis of underlying cancer varies, with cancer sometimes being discovered simultaneously with the arthritis diagnosis and other times being identified during subsequent investigation. Treatment of the underlying malignancy has been reported to result in resolution of the RS3PE signs and symptoms, suggesting a direct pathophysiological link between the two conditions.

Diagnosis and Diagnostic Criteria

Diagnosis of RS3PE is primarily clinical, based on the characteristic constellation of findings rather than specific laboratory markers. The diagnostic approach involves the following steps:

The diagnosis requires careful exclusion of other conditions that may present similarly. Comprehensive clinical evaluation is mandatory, particularly to rule out underlying malignancy. This evaluation should include appropriate cancer screening based on the patient’s age, risk factors, and clinical presentation.

Differential Diagnoses

Several conditions must be considered in the differential diagnosis of RS3PE to ensure accurate diagnosis and appropriate management:

• Seronegative Rheumatoid Arthritis: While this condition presents with symmetrical polyarthritis, it typically has a chronic, progressive course and lacks the prominent pitting edema characteristic of RS3PE. The dramatic response to low-dose steroids and rapid remission are more typical of RS3PE than seronegative rheumatoid arthritis.
• Reactive Arthritis: May present with acute-onset arthritis but typically follows a triggering infection and lacks the characteristic pitting edema pattern.
• Other Seronegative Polyarthropathies: Various seronegative conditions may present with polyarthritis but lack the distinctive pitting edema and rapid response to steroids.
• Infectious Causes: Viral and bacterial infections may cause transient arthritis but are typically associated with systemic symptoms and positive serologies for specific organisms.

Complications

Although RS3PE generally has a benign prognosis, several potential complications warrant consideration:

• Functional impairment during the acute phase, including inability to perform activities of daily living
• Underlying malignancy in paraneoplastic cases, which may represent the most significant concern
• Difficulty in maintaining remission in some cases, requiring adjunctive therapy with antimalarial agents such as hydroxychloroquine
• Recurrence of symptoms in some patients despite initial successful treatment, particularly if underlying malignancy is not adequately addressed

Treatment and Management

RS3PE demonstrates an exquisite and reliable response to corticosteroid therapy, which forms the cornerstone of treatment. The typical management approach includes:

• Initial Treatment: Low-dose prednisone or prednisolone, typically initiated at doses of 10-15 mg daily
• Treatment Duration: Initial therapeutic course typically lasts 4-6 weeks
• Dose Tapering: Gradual reduction of the corticosteroid dose after initial control of symptoms
• Adjunctive Therapy: Hydroxychloroquine may be added in cases where difficulty is encountered in maintaining remission at lower corticosteroid doses
• Long-term Outcome: Many patients achieve complete remission and can discontinue treatment without recurrence

Diuretic therapy and non-steroidal anti-inflammatory drugs may provide symptomatic relief but are typically insufficient as monotherapy. The rapid response to corticosteroids often occurs within days to weeks, with resolution of pitting edema and improvement in joint symptoms. This dramatic response to steroids can serve as both a diagnostic and therapeutic tool.

For patients with paraneoplastic RS3PE, treatment of the underlying malignancy is crucial. In documented cases, successful chemotherapy or other cancer treatment has resulted in complete resolution of the arthritis and edema, supporting the paraneoplastic nature of the condition. Physicians should maintain awareness that in patients where RS3PE recurs or proves difficult to manage, reassessment for occult malignancy may be warranted.

Prognosis and Outcome

The prognosis of RS3PE is generally favorable. Most patients experience complete resolution of symptoms following appropriate corticosteroid therapy. The condition is characterized by remission after withdrawal of treatment in many cases, distinguishing it from chronic rheumatologic conditions requiring long-term immunosuppression. The absence of joint erosion means that permanent structural damage does not occur, and functional recovery is typically complete.

However, the presence of an underlying malignancy significantly impacts overall prognosis. In cases where RS3PE represents a paraneoplastic syndrome, the long-term outcome depends on the nature of the underlying cancer and its treatment response. Nonetheless, in many documented cases, successful cancer treatment leads to resolution of the RS3PE manifestations, suggesting that addressing the underlying malignancy can result in dual benefit.

Clinical Pearls and Key Takeaways

• RS3PE is a rare but distinctive rheumatologic condition that should be considered in patients presenting with acute-onset symmetrical polyarthritis and prominent pitting edema
• The diagnosis is clinical, based on characteristic features rather than specific laboratory markers
• Seronegativity for rheumatoid factor is a defining feature that helps distinguish RS3PE from seropositive rheumatoid arthritis
• The dramatic and rapid response to low-dose corticosteroids is both a diagnostic clue and the primary treatment approach
• Thorough clinical evaluation to exclude underlying malignancy is essential, particularly in atypical presentations or when RS3PE proves difficult to manage
• In paraneoplastic cases, treatment of the underlying cancer may result in complete resolution of the RS3PE manifestations
• Long-term remission without continued treatment is achievable in most cases, making RS3PE one of the more favorable rheumatologic diagnoses

Frequently Asked Questions

Q: What does RS3PE stand for?

A: RS3PE stands for Remitting Seronegative Symmetrical Synovitis with Pitting Edema. The term accurately describes the key clinical features of the condition: its tendency to remit, the absence of rheumatoid factor, the symmetrical nature of the arthritis, and the characteristic pitting edema.

Q: How common is RS3PE?

A: RS3PE is an uncommon rheumatic disease, meaning it is relatively rare compared to other rheumatologic conditions such as rheumatoid arthritis. This rarity means many physicians may have limited experience with the condition, sometimes leading to diagnostic delays.

Q: Is RS3PE associated with permanent joint damage?

A: No, RS3PE does not cause joint erosion or permanent structural damage. One of the defining features is the absence of bony destruction on imaging studies, distinguishing it from erosive conditions like rheumatoid arthritis.

Q: Can RS3PE occur in younger patients?

A: While RS3PE predominantly affects elderly individuals, particularly those over 60 years of age, case reports have documented presentations in younger patients, including women under 50. However, this presentation is less common.

Q: What should be done if RS3PE is suspected?

A: If RS3PE is suspected based on clinical presentation, comprehensive evaluation should be undertaken including serological testing, imaging studies, and importantly, screening for underlying malignancy. A rheumatology consultation is recommended to confirm the diagnosis and initiate appropriate corticosteroid therapy.

Q: How long does treatment typically last?

A: Initial corticosteroid therapy typically lasts 4-6 weeks, with gradual tapering of the dose thereafter. However, the total duration may vary based on individual response. Many patients achieve complete remission and can discontinue treatment without recurrence.

Q: What is the relationship between RS3PE and cancer?

A: RS3PE can be a paraneoplastic syndrome, meaning it may occur as a manifestation of underlying malignancy. Various cancers have been reported in association with RS3PE, and treatment of the underlying cancer may result in resolution of the arthritis and edema.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete